961 followers
Congratulations to Alessio Cortellini on their public disclosure, "Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial." https://t.co/MzQT